GLP-1 drugs, originally for diabetes, show potential neuroprotective effects. Research suggests they may reduce brain inflammation, improve insulin signaling in the brain, and slow cognitive decline. While still under study, early findings indicate promise in supporting Alzheimer’s disease management.